Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
Meta Expands AI Training With Employee Activity Tracking Tools 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
ROCKVILLE, Md., March 28, 2017 -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate presentation at the 16th Annual Needham Healthcare Conference on Tuesday, April 4th at 12:10 PM ET.
Investors interested in arranging a meeting with the Company's management during this conference should contact the conference coordinator.
The presentation will be webcast live and may be accessed from the Event Calendar page of Sucampo's website at http://www.sucampo.com/investors/events-presentations/. A replay of the webcast will also be available on the Company's website for several days after the live event. To ensure a timely connection, it is recommended that users register at least 15 minutes prior to the scheduled webcast.
About Sucampo Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a pipeline of product candidates in clinical development. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow us on LinkedIn (Sucampo Pharmaceuticals).
Contact: Sucampo Pharmaceuticals, Inc. Silvia Taylor Senior Vice President, Investor Relations and Corporate Affairs 1-240-223-3718 [email protected]
